Contact
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
The prevalence of diabetes in Southern Africa has been increasing steadily over the years, leading to a rise in demand for anti-diabetes drugs.
Customer preferences: Patients in Southern Africa are increasingly seeking out more effective and affordable anti-diabetes drugs. They are also looking for drugs that have fewer side effects and are easier to administer.
Trends in the market: The anti-diabetes drugs market in Southern Africa has been witnessing a shift towards more innovative drugs that offer better treatment options for patients. This has been driven by the entry of new players into the market and the increasing competition among existing players. There has also been a growing trend towards the use of combination therapies, which involve the use of two or more drugs to manage diabetes.
Local special circumstances: One of the major challenges facing the anti-diabetes drugs market in Southern Africa is the lack of access to healthcare facilities, particularly in rural areas. This has led to a situation where a large number of people with diabetes are undiagnosed and untreated. Additionally, the high cost of anti-diabetes drugs is a major barrier to treatment for many patients.
Underlying macroeconomic factors: The rising prevalence of diabetes in Southern Africa can be attributed to a number of underlying macroeconomic factors, including changing dietary patterns, sedentary lifestyles, and increasing urbanization. These factors have led to a rise in the number of people with obesity and related health conditions, including diabetes. The economic growth in the region has also led to an increase in the number of people who can afford to pay for healthcare services, including anti-diabetes drugs.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)